The immunopathology of multiple sclerosis: an overview, Brain Pathol, vol.17, issue.2, pp.210-218, 2007. ,
Progressive multiple sclerosis: from pathogenic mechanisms to treatment, Brain, p.258, 2016. ,
Primary and secondary progressive multiple sclerosis ,
, J Neurol Sci, vol.206, issue.2, pp.153-158, 2003.
The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis, Brain J Neurol, 1999. ,
The natural history of primary progressive MS in British Columbia, Canada. Neurology, vol.65, issue.12, pp.1919-1923, 2005. ,
Epidemiology of Multiple Sclerosis, Neurol Clin, vol.34, issue.4, pp.919-958, 2016. ,
Temporal trends in the incidence of multiple sclerosis: A systematic review, Neurology, vol.71, issue.2, pp.129-164, 2008. ,
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, 1996. ,
Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review, NeuroToxicology, vol.61, pp.189-212, 2017. ,
, Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis, Hum Mol Genet, 2006.
, Sep, vol.15, issue.18, pp.2813-2837
Multiple sclerosis and environmental factors: the role of vitamin D, parasites, and Epstein-Barr virus infection, Acta Neurol Scand, vol.132, pp.46-55, 2015. ,
Safety of vitamin D3 in adults with multiple sclerosis, Am J Clin Nutr, vol.86, issue.3, pp.645-651, 2007. ,
Immunomodulatory effects of Vitamin D in multiple sclerosis, Brain, vol.132, issue.5, pp.1146-60, 2009. ,
Epstein-Barr Virus Infection and Multiple Sclerosis: A Review, J Neuroimmune Pharmacol, vol.5, issue.3, pp.271-278, 2010. ,
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel, Mult Scler J, vol.17, issue.10, pp.1185-93, 2011. ,
, Barr virus in oral shedding of children with multiple sclerosis, Neurology, vol.81, issue.16, pp.1392-1399, 2013.
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI, Neurology, vol.73, issue.1, pp.32-38, 2009. ,
Smoking does not influence disability accumulation in primary progressive multiple sclerosis, Eur J Neurol, vol.128, issue.6, pp.1461-1466, 2005. ,
Natural history of multiple sclerosis: a unifying concept, Brain, vol.129, issue.3, pp.606-616, 2006. ,
, Defining the clinical course of multiple sclerosis: The 2013 revisions, Neurology, vol.83, issue.3, pp.278-86, 2014.
, Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, N Engl J Med, 2017.
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial, Ann Neurol, vol.61, issue.1, pp.14-24, 2007. ,
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial, Ann Neurol, vol.66, issue.4, pp.460-71, 2009. ,
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet, vol.387, pp.1075-84, 2016. ,
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study, Mult Scler J, vol.22, issue.13, pp.1900-1913, 2010. ,
Natural history of multiple sclerosis in a population-based cohort, Eur J Neurol, 2008. ,
Modelling the natural history of primary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, 2015. ,
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease, Poser CM, vol.343, pp.584-94, 2000. ,
, New diagnostic criteria for multiple sclerosis: Guidelines for research protocols, Ann Neurol, vol.13, issue.3, pp.227-258, 1983.
, Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria, Ann Neurol, vol.69, issue.2, pp.292-302, 2011.
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-1444, 1983. ,
, Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis, Brain, vol.135, issue.10, pp.2925-2962, 2012.
The natural history of primary progressive multiple sclerosis, Neurology, vol.73, issue.23, pp.1996-2002, 2009. ,
, Relapses and disability accumulation in progressive multiple sclerosis, Neurology, 2015.
Sastre-Garriga J TA. Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data, Ann Neurol, vol.63, issue.6, pp.633-638, 2005. ,
, Long-term disability progression in primary progressive multiple sclerosis: a 15-year study, Brain, vol.140, issue.11, pp.2814-2823, 2017.
Validating Predictors of Disease Progression in a Large Cohort of Primary-Progressive Multiple Sclerosis Based on a Systematic Literature Review. Villoslada P, editor, PLoS ONE, vol.9, issue.3, p.92761, 2014. ,
, Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis, Mult Scler J, vol.24, issue.5, pp.642-652, 2018.